Essa Pharma
Investors/Media

With a focus on the development of small molecule drugs for the treatment of cancer, the goal at ESSA is to develop a pipeline of oncology therapeutics. We will continue to research innovative ideas with the goal of providing a promising future for the patients and community we serve.

With a focus on the development of small molecule drugs for the treatment of cancer, the goal at ESSA is to develop a pipeline of oncology therapeutics. We will continue to research innovative ideas with the goal of providing a promising future for the patients and community we serve.

Latest News
Feb 13, 2024

Combination of masofaniten plus enzalutamide continues to be well tolerated with deep and durable reductions in PSA in Phase 1 dose escalation in patients with mCRPC, including 81% of patients...

Feb 6, 2024

ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced that...

Jan 25, 2024

Combination of masofaniten plus enzalutamide continues to be well tolerated with deep and durable reductions in PSA in patients with mCRPC Phase 2 dose expansion currently underway at the RP2CDs...

View All News

Stock Performance

Last Price


Change


Volume

NASDAQEPIX

Investor & Media Contacts

Investor Contact
Argot Partners
essa@argotpartners.com

Media Contact
Argot Partners
essa@argotpartners.com